التفاصيل البيبلوغرافية
| العنوان: |
Impact of prior chemotherapy on outcomes with trabectedin/pegylated liposomal doxorubicin in recurrent ovarian cancer. |
| المؤلفون: |
Pignata, Sandro1 s.pignata@istitutotumori.na.it, Scambia, Giovanni2, Villanucci, Alessandro3, Naglieri, Emanuele4, Ibarbia, Mikel Arruti5, Brusa, Federica6, Bourgeois, Hugues7, Sorio, Roberto8, Casado, Antonio9, Reichert, Dietmar10, Dopchie, Catherine11, De Rivas, Beatriz12, Tanović, Adnan12, de Sande, Luis M.13 |
| المصدر: |
Cancer & Chemotherapy Reviews. 2022, Vol. 17 Issue 2, p23-28. 6p. |
| مصطلحات موضوعية: |
*TRABECTEDIN, *OVARIAN cancer, *DOXORUBICIN, *CANCER chemotherapy, *PROGRESSION-free survival |
| مستخلص: |
Aim: The aim of this study was to evaluate the effect of number of prior chemotherapy lines, and the possible impact of poly (ADP-ribose) polymerase inhibitor (PARPi) pre-treatment, on the efficacy of trabectedin/pegylated liposomal doxorubicin (PLD) in women with platinum-sensitive recurrent ovarian cancer (ROC). Patients and methods: A post hoc analysis of the pan-European NIMES-ROC study was performed. Women with platinumsensitive ROC who received ≥ 1 cycle of trabectedin/PLD (n = 218) were enrolled from routine clinical practice. Results: No differences in progression-free survival, overall survival, or safety profile were seen between patients pretreated with ≥ 2 prior platinum-based lines versus recipients of < 2 lines of prior chemotherapy. Among seven patients pretreated with PARPi, trabectedin/PLD provided some clinical benefit. Conclusion: Trabectedin/PLD activity was retained in ROC patients pretreated with ≥ 2 prior platinum-based lines. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
